SOD1 and amyotrophic lateral sclerosis: HuMab IP delivery to ALS mouse models with longer time for disease onset (G37R, G85R, or low-copy G93A) and endpoints other than survival extension (reduction in motor neuron loss, reduction in mutant hSOD1, or muscle strength and motor assessments) may afford a clearer picture of HuMab efficacy.